These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 3739328)

  • 1. Current (safety) issues in the screening of donor blood and the preparation of pure blood components. November 7-8, 1985. Oss, The Netherlands.
    Vox Sang; 1986; 51 Suppl 1():1-72. PubMed ID: 3739328
    [No Abstract]   [Full Text] [Related]  

  • 2. Current issues in transfusion medicine in Norway.
    Flesland O; Seghatchian J
    Transfus Apher Sci; 2005 Feb; 32(1):7-10. PubMed ID: 15737866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The donor of blood and its components.
    Högman CF
    Schweiz Med Wochenschr Suppl; 1991; 43():111-4. PubMed ID: 1843033
    [No Abstract]   [Full Text] [Related]  

  • 4. ['Variant of Creutzfeldt-Jacob disease and blood transfusion'; report of the Dutch Health Council].
    van Aken WG
    Ned Tijdschr Geneeskd; 2001 Jul; 145(30):1444-7. PubMed ID: 11503311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Implementation of apparative hemapheresis for collecting blood component stores. Recommendations of the Hemapheresis Commission of the German Society of Transfusion Medicine and Immunohematology].
    Kretschmer V; Borberg H; Giannitsis D; Kamanabroo D; Mempel W; Müller V; Müller N; Neumeyer H
    Infusionsther Klin Ernahr; 1987 Sep; 14 Suppl 4():57-64. PubMed ID: 3679531
    [No Abstract]   [Full Text] [Related]  

  • 6. Donor screening.
    Silvergleid AJ
    Clin Lab Med; 1992 Dec; 12(4):669-83. PubMed ID: 1286557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evaluation of the leuko-reductive efficacy of single-donor erythropheresis procedures].
    Domingo JM; Rabasa P; Chueca P; Medarde A
    Sangre (Barc); 1999 Jun; 44(3):238-40. PubMed ID: 10481589
    [No Abstract]   [Full Text] [Related]  

  • 8. Can (should) apheresis supplant whole blood collection?
    Ciavarella D
    Transfus Sci; 1992 Apr; 13(2):201-5. PubMed ID: 10148126
    [No Abstract]   [Full Text] [Related]  

  • 9. Surveillance of risk profiles among new and repeat blood donors with transfusion-transmissible infections from 1995 through 2003 in the Netherlands.
    Van der Bij AK; Coutinho RA; Van der Poel CL
    Transfusion; 2006 Oct; 46(10):1729-36. PubMed ID: 17002629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maximizing blood component donations.
    Fuller MJ
    Vox Sang; 2000; 78 Suppl 2():47-9. PubMed ID: 10938926
    [No Abstract]   [Full Text] [Related]  

  • 11. Successful removal of Chlamydia pneumoniae from plateletpheresis products collected using automated leukoreduction hemapheresis techniques.
    Webley W; Stuart E; Cirino F; Cahill F; Stec T; Andrzejewski C
    J Clin Apher; 2006 Oct; 21(3):195-201. PubMed ID: 16570261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Innovations in blood donor screening and blood collection.
    Smith JW; Forsberg JE; Gilcher RO
    Curr Hematol Rep; 2002 Nov; 1(2):129-33. PubMed ID: 12901134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Leukocyte depletion of blood products: a requirement for improvement of quality and safety].
    De Pauw BE; Van den Bos A
    Ned Tijdschr Geneeskd; 2000 Sep; 144(36):1754-6. PubMed ID: 10992905
    [No Abstract]   [Full Text] [Related]  

  • 14. [Serological study on chagasic blood donors in 4 blood banks of Bogota City].
    Guhl F; Canosa A; Ruiź G; de Sánchez N
    Rev Latinoam Microbiol; 1979; 21(4):225-7. PubMed ID: 121623
    [No Abstract]   [Full Text] [Related]  

  • 15. TRALI risk reduction: donor and component management strategies.
    Eder AF; Benjamin RJ
    J Clin Apher; 2009; 24(3):122-9. PubMed ID: 19365816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Situation of the blood banks in the region of the Americas, 1994-1995.
    Epidemiol Bull; 1997 Mar; 18(1):11-2. PubMed ID: 9197084
    [No Abstract]   [Full Text] [Related]  

  • 17. What happens to donated blood?
    Robinson A
    CMAJ; 1995 Feb; 152(4):521-4. PubMed ID: 7859200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of donating multiple products in a single apheresis collection: are we expecting too much?
    Strauss RG
    J Clin Apher; 2003; 18(3):135-40. PubMed ID: 14569607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. "Guidance for industry: current good manufacturing practice for blood and blood components: (1). Quarantine and disposition of units from prior collections from donors with repeatedly reactive screening test for antibody to hepatitis C virus (anti-HCV); (2). Supplemental testing, and the notification of consignees and blood recipients of donor test results for anti-HCV;" availability--FDA. Notice.
    Fed Regist; 1998 Oct; 63(203):56198-9. PubMed ID: 10185838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blood bank situation in Latin America, 1996: serological markers for communicable diseases in blood donors.
    Epidemiol Bull; 1998 Sep; 19(3):12-4. PubMed ID: 9863270
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.